Insight

Tejas Patil: Why biomarkers like PDL1 and TMB aren’t always associated with ‘hot’ or ‘cold’ immune TME

Tejas Patil/X

Nov 25, 2024, 17:49

Tejas Patil: Why biomarkers like PDL1 and TMB aren’t always associated with ‘hot’ or ‘cold’ immune TME

Tejas Patil, Thoracic oncologist CU Cancer Center, shared a post by Cancer Cell on X:

“Nice article that gets into why biomarkers like PDL1 and TMB aren’t always associated with ‘hot’ or ‘cold’ immune TME.”

Quoting Cancer Cell’s post:

“Online Now: Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.”

Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.

Authors: David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry, Emmanuel S. Antonarakis, Stephanie L. Graff, Michael J. Hall, Hossein Borghaei, Dave S.B. Hoon, Stephen V. Liu, Patrick C. Ma, Rana R. McKay, Trisha Wise-Draper, John Marshall, George W. Sledge, David Spetzler, Hao Zhu

Tejas Patil

Andreas Seeber Andrew Elliott biomarkers cancer Cancer Cell Dave S B Hoon David Hsiehchen David Spetzler Emmanuel S Antonarakis George W. Sledge Hao Zhu Hossein Borghaei immune cell infiltration Joanne Xiu John Marshall lymphoid activation Michael J Hall OncoDaily Oncology Patrick C. Ma Rana R. McKay Stephanie L. Graff Stephen V Liu Tejas Patil Trisha Wise-Draper Wafik El-Deiry

Leukemia: Symptoms, Causes, Types, Diagnosis & Treatment

U.S. FDA Approval of Ziihera for the Previously Treated, Unresectable or IHC 3+ Biliary Tract Cancer

ASCO GI 2025 - Everything You Need To Know About Biggest Gastrointestinal cancer Symposium

Side Effects of Radiotherapy: Risks and What to Know

Isabel Rubio has been elected as the President of the European Cancer Organisation for 2026-2027

Special Coverage